JP2023524668A - 若年性特発性関節炎を治療するための材料及び方法 - Google Patents

若年性特発性関節炎を治療するための材料及び方法 Download PDF

Info

Publication number
JP2023524668A
JP2023524668A JP2022565551A JP2022565551A JP2023524668A JP 2023524668 A JP2023524668 A JP 2023524668A JP 2022565551 A JP2022565551 A JP 2022565551A JP 2022565551 A JP2022565551 A JP 2022565551A JP 2023524668 A JP2023524668 A JP 2023524668A
Authority
JP
Japan
Prior art keywords
tnf
antibody
jia
amino acid
pediatric patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565551A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021220140A5 (https=
JP2023524668A5 (https=
Inventor
ベンズリー，カレン
クラーク，マイケル
ル，ジョスリン
シュー，ジェンファ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Priority claimed from PCT/IB2021/053429 external-priority patent/WO2021220140A1/en
Publication of JP2023524668A publication Critical patent/JP2023524668A/ja
Publication of JPWO2021220140A5 publication Critical patent/JPWO2021220140A5/ja
Publication of JP2023524668A5 publication Critical patent/JP2023524668A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Farming Of Fish And Shellfish (AREA)
JP2022565551A 2020-04-27 2021-04-26 若年性特発性関節炎を治療するための材料及び方法 Pending JP2023524668A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063015902P 2020-04-27 2020-04-27
US202063015889P 2020-04-27 2020-04-27
US202063015894P 2020-04-27 2020-04-27
US63/015,902 2020-04-27
US63/015,894 2020-04-27
US63/015,889 2020-04-27
PCT/IB2021/053429 WO2021220140A1 (en) 2020-04-27 2021-04-26 Materials and methods for treating juvenile idiopathic arthritis

Publications (3)

Publication Number Publication Date
JP2023524668A true JP2023524668A (ja) 2023-06-13
JPWO2021220140A5 JPWO2021220140A5 (https=) 2024-05-01
JP2023524668A5 JP2023524668A5 (https=) 2024-05-01

Family

ID=78336251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565551A Pending JP2023524668A (ja) 2020-04-27 2021-04-26 若年性特発性関節炎を治療するための材料及び方法

Country Status (9)

Country Link
EP (1) EP4143226A4 (https=)
JP (1) JP2023524668A (https=)
KR (1) KR20230005284A (https=)
CN (1) CN115461365A (https=)
AU (1) AU2021263136A1 (https=)
BR (1) BR112022021766A2 (https=)
CA (1) CA3127807A1 (https=)
IL (1) IL297623A (https=)
MX (1) MX2022013502A (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509988A (ja) * 2016-02-05 2019-04-11 ヤンセン バイオテツク，インコーポレーテツド １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961746B (zh) * 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
KR20190113858A (ko) * 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509988A (ja) * 2016-02-05 2019-04-11 ヤンセン バイオテツク，インコーポレーテツド １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY AND SAFETY OF INTRAVENOUS GOLIMUMAB IN PEDIATRIC, vol. NCT02277444, JPN6025017030, ISSN: 0005748813 *
ANNALS OF THE RHEUMATIC DISEASES, vol. 77, no. 1, JPN6025017028, 2018, pages 21 - 29, ISSN: 0005583728 *
ANNALS OF THE RHEUMATIC DISEASES, vol. 78, JPN6025017029, 2019, pages 966, ISSN: 0005748814 *
ARTHRITIS RESEARCH & THERAPY, vol. Vol. 18, article number 272, JPN6025017026, 2016, pages 1 - 12, ISSN: 0005583730 *
CURRENT OPINION IN RHEUMATOLOGY, vol. 27, no. 5, JPN6025017027, 2015, pages 505 - 510, ISSN: 0005583729 *

Also Published As

Publication number Publication date
EP4143226A1 (en) 2023-03-08
EP4143226A4 (en) 2024-05-29
CN115461365A (zh) 2022-12-09
MX2022013502A (es) 2023-02-01
CA3127807A1 (en) 2021-10-27
KR20230005284A (ko) 2023-01-09
AU2021263136A1 (en) 2023-01-05
IL297623A (en) 2022-12-01
BR112022021766A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
US12291566B2 (en) Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
JP2022137167A (ja) 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
JP2025098055A (ja) 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
JP2025157225A (ja) 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
US20210340245A1 (en) Materials and Methods for Treating Juvenile Idiopathic Arthritis
JP7689074B2 (ja) 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
JP2023524668A (ja) 若年性特発性関節炎を治療するための材料及び方法
JP2025084901A (ja) 乾癬性関節炎の治療方法で使用するための抗ｔｎｆ抗体組成物
EA052133B1 (ru) Материалы и способы лечения ювенильного идопатического артрита
EA047762B1 (ru) Композиции антитела к фно и способы лечения ювенильного идиопатического артрита

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209